Prevention and health services delivery.

The burden of stroke to the health care system in the United States continues to increase. Stroke-related hospital admissions grew from 580 000 in 1988 to 820 000 in 1997, an 18.6% increase after age adjustment.1 More effective stroke prevention provides the primary means of reducing these alarming statistics. This can be accomplished through better implementation of known preventive strategies2 and through research into new approaches to stroke prevention. Diet can affect stroke risk, with epidemiological studies indicating an inverse relationship between fruit and vegetable consumption and cardiovascular events.2 For example, one study including individuals free of cardiovascular disease at baseline found that the relative risk (RR) of stroke was reduced by 31% (RR, 0.69; 95% CI, 0.52 to 0.92) for persons in the highest quintile of fruit and vegetable intake.3 Analysis of data from the National Health and Nutrition Examination Survey (NHANES) Epidemiologic Follow-up Study supports these results.4 The study included 9608 adults aged 25 to 74 years who were free of cardiovascular disease at a baseline evaluation between 1971 and 1975. Consumption of fruits and vegetables ≥3 times per day compared with <1 time per day was associated with a 27% lower stroke incidence (RR, 0.73; 95% CI, 0.57 to 0.95) after adjustment for potential confounders, suggesting the benefit is not attributable to a healthy-user effect. The results reinforce present recommendations for an intake of 5 servings of fruits and vegetables daily. Because fruits and vegetables contain antioxidants, antioxidant food supplements might be expected to have similar benefits. However, a 3-year study of patients with coronary heart disease, low levels of high-density lipoprotein cholesterol, and normal levels of low-density lipoprotein cholesterol found no reduction in cardiovascular end points (death, myocardial infarction, stroke, and revascularization procedures) with the use of antioxidant supplements (800 IU …

[1]  Gwyn McClelland.  Survivors , 1891, The Hospital.

[2]  P. Touboul,et al.  Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.

[3]  T. Gross,et al.  Problems with drug-eluting coronary stents--the FDA perspective. , 2004, The New England journal of medicine.

[4]  T. Bajwa,et al.  Protected carotid-artery stenting versus endarterectomy in high-risk patients. , 2004, The New England journal of medicine.

[5]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[6]  L. Lisabeth,et al.  Stroke Risk After Transient Ischemic Attack in a Population-Based Setting , 2004, Stroke.

[7]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[8]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[9]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[10]  J. Tu,et al.  The high risk of stroke immediately after transient ischemic attack , 2004, Neurology.

[11]  R. Peto,et al.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial , 2004, The Lancet.

[12]  R. Gliklich,et al.  Get with the guidelines for cardiovascular secondary prevention: pilot results. , 2004, Archives of internal medicine.

[13]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[14]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[15]  V. Hachinski.  Advances in stroke 2003: introduction. , 2004, Stroke.

[16]  D. Nilasena,et al.  Multistate improvement in process and outcomes of carotid endarterectomy. , 2004, Journal of vascular surgery.

[17]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.

[18]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[19]  P. Akins,et al.  How Effective Are “Community” Stroke Screening Programs at Improving Stroke Knowledge and Prevention Practices?: Results of a 3-Month Follow-Up Study , 2003, Stroke.

[20]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[21]  M. Hennerici,et al.  Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.

[22]  F. Silver,et al.  Advertising Strategies to Increase Public Knowledge of the Warning Signs of Stroke , 2003, Stroke.

[23]  P. Sandercock,et al.  Very Early Risk of Stroke After a First Transient Ischemic Attack , 2003, Stroke.

[24]  A. Tjønneland,et al.  Intake of fruit and vegetables and the risk of ischemic stroke in a cohort of Danish men and women. , 2003, The American journal of clinical nutrition.

[25]  H. Diener,et al.  The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.

[26]  E. Topol,et al.  Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials , 2003, The Lancet.

[27]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[28]  S. Leurgans,et al.  Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. , 2003, JAMA.

[29]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[30]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[31]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[32]  P. Sandercock,et al.  In-Hospital Care Pathways for Stroke: A Cochrane Systematic Review , 2003, Stroke.

[33]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[34]  S. Leurgans,et al.  Awareness, treatment, and control of vascular risk factors in African Americans with stroke , 2003, Neurology.

[35]  Matti Lehtihalmes,et al.  Poststroke Depression: An 18-Month Follow-Up , 2003, Stroke.

[36]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[37]  R. Kronmal,et al.  Serum potassium level and dietary potassium intake as risk factors for stroke , 2002, Neurology.

[38]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[39]  R. Collins,et al.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[40]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[41]  Jiang He,et al.  Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. , 2002, The American journal of clinical nutrition.

[42]  J. Roseman,et al.  Absence of risk factor change in young adults after family heart attack or stroke: the CARDIA Study. , 2002, American journal of preventive medicine.

[43]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[44]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[45]  C. Viscoli,et al.  A clinical trial of estrogen-replacement therapy after ischemic stroke , 2002 .

[46]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[47]  A. Demchuk,et al.  Improving Delivery of Acute Stroke Therapy: The TLL Temple Foundation Stroke Project , 2002, Stroke.

[48]  A. Coats.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[49]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[50]  R. Hobson.  Update on the Carotid Revascularization Endarterectomy versus Stent Trial (CREST) protocol. , 2002, Journal of the American College of Surgeons.

[51]  L. Goldstein,et al.  Low rate of complications of cerebral angiography in routine clinical practice , 2001, Neurology.

[52]  U. de Faire,et al.  Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy , 2001, Hypertension.

[53]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[54]  Jan A Staessen,et al.  Cardiovascular protection and blood pressure reduction: a meta-analysis , 2001, The Lancet.

[55]  Jing Fang,et al.  Trend of Stroke Hospitalization, United States, 1988–1997 , 2001, Stroke.

[56]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[57]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[58]  I. Kronzon,et al.  Primary prevention of ischemic stroke. , 2001, Circulation.

[59]  P. Whelton,et al.  Dietary Potassium Intake and Risk of Stroke in US Men and Women: National Health and Nutrition Examination Survey I Epidemiologic Follow-Up Study , 2001, Stroke.

[60]  A. Gawlinski,et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.

[61]  J. Hsia,et al.  Postmenopausal Hormone Therapy and Risk of Stroke: The Heart and Estrogen-progestin Replacement Study (HERS) , 2001, Circulation.

[62]  P. Wolf,et al.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.

[63]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[64]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[65]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[66]  D Spiegelman,et al.  Fruit and vegetable intake in relation to risk of ischemic stroke. , 1999, JAMA.

[67]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[68]  A. Davies,et al.  Endarterectomy for asymptomatic carotid artery stenosis , 1995, BMJ.